Loading…
arrow_back View All Dates
Wednesday, September 16
 

7:30am EDT

Networking Breakfast
Wednesday September 16, 2026 7:30am - 8:30am EDT

Wednesday September 16, 2026 7:30am - 8:30am EDT
Grand Ballroom

7:30am EDT

Registration
Wednesday September 16, 2026 7:30am - 6:00pm EDT

Wednesday September 16, 2026 7:30am - 6:00pm EDT
West Lobby

8:35am EDT

Opening Remarks
Wednesday September 16, 2026 8:35am - 8:45am EDT

Speakers
avatar for Diana Gowe

Diana Gowe

Director, Global Strategic Analytics, Johnson & Johnson

Wednesday September 16, 2026 8:35am - 8:45am EDT
Junior Ballroom

8:45am EDT

Keynote: Building the Next Generation of Intelligence Organizations
Wednesday September 16, 2026 8:45am - 9:15am EDT
Preparing for the Next Era of Business Decision-Making
Competitive intelligence is entering a new era. AI is transforming how information is gathered and analyzed, but the bigger shift is how organizations expect intelligence teams to create value. Increasingly, success is measured not by the information delivered, but by the strategic decisions intelligence helps shape.
Potential discussion topics include:
  • How AI is changing—not replacing—the role of competitive intelligence.
  • Why competitive advantage increasingly comes from interpretation, scenario planning, and strategic decision support rather than information gathering alone.
  • How market research, competitive intelligence, forecasting, analytics, and strategy are becoming more integrated across organizations.
  • The operating models, capabilities, and leadership skills that will define the next generation of intelligence organizations.
  • How executive expectations of intelligence teams have evolved—and what business leaders expect today.
  • Building cross-functional partnerships that increase the influence and business impact of intelligence teams.


Moderators
avatar for Diana Gowe

Diana Gowe

Director, Global Strategic Analytics, Johnson & Johnson

Speakers
avatar for Evelyn Greene, MPH

Evelyn Greene, MPH

Global Head of Market Research and Competitive Insights, Sanofi
Evelyn Greene, MPH, is Global Head of Market Research and Competitive Insights at Sanofi and a recognized leader in the application of strategic intelligence to biopharmaceutical decision-making. She oversees a global organization responsible for delivering integrated market research... Read More →
avatar for Frank Sama, MBA

Frank Sama, MBA

Competitive Intelligence Excellence and Cross-Functional Lead, Sanofi
Frank Sama, MBA, is the Competitive Intelligence Excellence and Cross-Functional Lead at Sanofi, where he leads initiatives to strengthen CI capabilities and advance strategic decision-making across the organization. With more than 30 years of experience spanning biopharmaceuticals... Read More →
Wednesday September 16, 2026 8:45am - 9:15am EDT
Junior Ballroom

9:15am EDT

Keynote: Consumerization and Cash-Pay Access in Pharma: TrumpRx, the GLP-1 boom, and the branded-drug categories that may be next
Wednesday September 16, 2026 9:15am - 9:45am EDT
Consumerization is beginning to reshape how patients discover, evaluate and access branded prescription medicines in the US. Starting with obesity, this talk will take a practical look at the potential or actual direct-to-patient market, where this consumer-led demand may head next and how commercial teams should get ahead of it.
  • The rise of cash-pay consumerization in US Pharma, powered by TrumpRx and direct-to-patient channels
  • Obesity as the leading example
  • Which categories are next, and what it means for commercial strategy

Speakers
avatar for Pooja Goyal

Pooja Goyal

Engagement Manager, Lifescience Dynamics

avatar for Peter Kelly

Peter Kelly

Principal, Lifescience Dynamics

Wednesday September 16, 2026 9:15am - 9:45am EDT
Junior Ballroom

9:45am EDT

Networking Break
Wednesday September 16, 2026 9:45am - 10:30am EDT

Wednesday September 16, 2026 9:45am - 10:30am EDT
Grand Ballroom

10:30am EDT

Primary Intelligence, Strategic Advantage: Unlocking Success through Deeper Insights
Wednesday September 16, 2026 10:30am - 11:00am EDT
In a rapidly evolving pharmaceutical landscape shaped by artificial intelligence, regulatory change, commercialization pressures, and increasing volatility, uncertainty, complexity, and ambiguity (VUCA), this keynote will highlight the strategic value of Primary Competitive Intelligence (CI). The session will examine how primary CI, grounded in direct and actionable real-world insights, can support timely strategic adjustments, strengthen decision-making, and enhance competitive advantage across the entire product lifecycle, from early-stage assessment through late lifecycle management. 
  
Attendees will gain a practical understanding of how to effectively integrate primary CI into strategic planning and execution. The presentation will further demonstrate how deeper insights, generated through a structured four-pronged methodology, can translate into measurable business impact and sustainable strategic advantage.

Speakers
avatar for Baljit Singh, Ph.D.

Baljit Singh, Ph.D.

CEO, INOVIS AG

Wednesday September 16, 2026 10:30am - 11:00am EDT
Junior Ballroom

11:00am EDT

Keynote: Inside the Executive Decision Room: How Executive Teams Evaluate Portfolio, Commercial and Business Development Decisions
Wednesday September 16, 2026 11:00am - 11:30am EDT
Using UroGen’s evolution from JELMYTO to ZUSDURI as a real-world lens, the discussion would explore how market intelligence informs executive decision-making as a company and its portfolio mature. It would move from the lessons gained through JELMYTO, to how those insights informed decisions around ZUSDURI and the broader portfolio, and ultimately to how leadership evaluates future internal and external growth opportunities.
 
  • What the first commercial success teaches you about the next opportunity
  • How leaders decide whether to build, buy, partner or pass
  • When intelligence provides the conviction to act or signals it is time to walk away
 



Speakers
avatar for Liz Barrett

Liz Barrett

President and Chief Executive Officer, UroGen
Liz is a highly regarded industry leader with extensive experience leading, building and growing organizations at Fortune 100 pharmaceutical companies before moving to a biotech company. She has been recognized as one of Fortune’s Most Powerful Women and Forbes 50 over 50 among... Read More →
avatar for Timothy Simon

Timothy Simon

SVP, Business Development and Portfolio Strategy, UroGen
Timothy Simon is a seasoned pharmaceutical executive with broad experience spanning Commercial Operations, M&A, Corporate Development, and Product Portfolio Strategy. He brings a strong track record of leadership across both large pharmaceutical companies and emerging biotech firms.Before... Read More →
Wednesday September 16, 2026 11:00am - 11:30am EDT
Junior Ballroom

11:30am EDT

Advisory Board Town Hall
Wednesday September 16, 2026 11:30am - 12:00pm EDT

Speakers
avatar for Ana Newnam

Ana Newnam

Competitive Intelligence Team Lead, BMS
Ana Newnam is the Competitive Intelligence Team Lead at Bristol Myers Squibb, part of the Enterprise Strategy group. Ana joined Bristol Myers Squibb in 2016 where she currently leads enterprise-wide strategic intelligence efforts spanning oncology, cell therapy, immunology, cardiovascular... Read More →
avatar for Diana Gowe

Diana Gowe

Director, Global Strategic Analytics, Johnson & Johnson

avatar for Christopher Salatto

Christopher Salatto

Head of Competitive Intelligence, Pfizer
Chris serves as Head of Competitive Intelligence at Pfizer. In this role he leads a global team of experts skilled at building a comprehensive view of the pharma environment, from the asset through sector levels, and integrating these knowledge and insights into every level of decision-making... Read More →
avatar for Maureen Nail, PhD, MBA

Maureen Nail, PhD, MBA

Director, Oncology Competitive Intelligence, AbbVie

Wednesday September 16, 2026 11:30am - 12:00pm EDT
Junior Ballroom

12:00pm EDT

Networking Lunch
Wednesday September 16, 2026 12:00pm - 1:00pm EDT

Wednesday September 16, 2026 12:00pm - 1:00pm EDT
Grand Ballroom

12:55pm EDT

Track A Chair
Wednesday September 16, 2026 12:55pm - 1:00pm EDT

Speakers
avatar for Diana Gowe

Diana Gowe

Director, Global Strategic Analytics, Johnson & Johnson

Wednesday September 16, 2026 12:55pm - 1:00pm EDT

12:55pm EDT

Track B Chair
Wednesday September 16, 2026 12:55pm - 1:00pm EDT

Speakers
avatar for Christopher Salatto

Christopher Salatto

Head of Competitive Intelligence, Pfizer
Chris serves as Head of Competitive Intelligence at Pfizer. In this role he leads a global team of experts skilled at building a comprehensive view of the pharma environment, from the asset through sector levels, and integrating these knowledge and insights into every level of decision-making... Read More →
Wednesday September 16, 2026 12:55pm - 1:00pm EDT

12:55pm EDT

Track C Chair
Wednesday September 16, 2026 12:55pm - 1:00pm EDT

Speakers
avatar for Maureen Nail, PhD, MBA

Maureen Nail, PhD, MBA

Director, Oncology Competitive Intelligence, AbbVie

Wednesday September 16, 2026 12:55pm - 1:00pm EDT

1:00pm EDT

First Look: What 135 Life Sciences CI Professionals Told Us Actually Works in 2026
Wednesday September 16, 2026 1:00pm - 1:30pm EDT
Join us for the debut release of this year's Annual Life Sciences CI Survey, capturing insights from 135 competitive intelligence professionals across the industry, covering:

  • Industry Benchmarks: CI budget and team size trends, AI maturity, effective delivery channels, and stakeholder engagement models
  • Maximizing CI Impact: What actually drives senior leadership reach, strategic influence, and stakeholder satisfaction, backed by new correlation analysis
  • AI Adoption: Practical CI use cases, internal pressure to adopt, realized ROI, and the barriers still holding teams back


Speakers
avatar for Matt Blandford

Matt Blandford

VP, Business Development, Sedulo Group

Wednesday September 16, 2026 1:00pm - 1:30pm EDT
Junior Ballroom C

1:00pm EDT

Why China Demands a Different Competitive Intelligence Playbook
Wednesday September 16, 2026 1:00pm - 1:30pm EDT
In recent years, China has become a global leader in oncology and immunology innovation and a key player in the commercial market for multinational pharma, yet it remains a persistent CI blind spot. Secondary data can be hard to access, as early clinical signals are often buried in China-based platforms and investigator-led trials. Robust primary intelligence can be challenging to gather due to language and cultural barriers. This leaves many Western CI teams exposed to delayed insights and reactive decision-making...even if your organization has a presence in China. 
 
Standard global frameworks fail to capture the realities of the China market, including unique access dynamics, rapid regulatory evolution and an intensifying Western race to license or acquire breakthrough assets, all set against shifting geopolitical pressures. 
 
This session sets out a practical framework to move China from a regional afterthought to a central pillar of global CI capability, actively driving insights and strategic decisions.
 

 


Speakers
avatar for Bharat Jain

Bharat Jain

Senior Principal, Prescient Healthcare Group

avatar for Jatin Gupta

Jatin Gupta

Client Partner, Prescient Healthcare Group
Jatin is a Client Partner at Prescient and has been with the company since 2014. He holds a Master’s degree in Biotechnology from the University of Manchester and has worked in the pharmaceutical analysis divisions of several major organizations, including Bloomberg. At Prescient... Read More →
Wednesday September 16, 2026 1:00pm - 1:30pm EDT
Junior Ballroom D

1:00pm EDT

Can Agentic AI Make CI Faster, Cheaper, Better?
Wednesday September 16, 2026 1:00pm - 1:30pm EDT
CI is bought twice: first the data subscriptions, then the manual work of synthesizing them. Two expensive purchases that still leave a team working from the same incomplete picture, where records are stale, signals late, and a shift in the landscape means doing much of the work again. That is why CI has always had to pick two of faster, cheaper and better. This session shows what changes when one system holds both layers: a data layer that is broader and fresher, and an agentic layer that turns an objective into a complete, cited analysis. Faster, cheaper, better, all three, with the team's time going to judgment rather than assembly. Live demos of Ferma's agentic AI suite, including a competitive landscape built on stage. 
 
Key takeaways 
  • Why buying data and buying synthesis still leaves a team working from an incomplete picture 
  • What changes when the data layer and the agentic layer become one system 
  • Why a refresh stops meaning doing much of the work again from scratch 
  • A competitive landscape, built live on stage, on a disease the room picks 

Speakers
avatar for Sriram Subramanian

Sriram Subramanian

Chief Executive Officer, Ferma

Wednesday September 16, 2026 1:00pm - 1:30pm EDT
Junior Ballroom F

1:35pm EDT

Decision Intelligence: What Integrated Insights Actually Looks Like
Wednesday September 16, 2026 1:35pm - 2:05pm EDT
  • Explore the convergence of CI, analytics, forecasting, market research, and strategy  

  • Debate where intelligence organizations should sit in the future  

  • Examine emerging operating models across pharma
Moderators
avatar for Heather Rumancik

Heather Rumancik

Director of Competitive Intelligence, AbbVie
Heather Rumancik is a competitive intelligence leader with a passion for connecting people, data, and technology to generate meaningful business insights. As Director of Competitive Intelligence at AbbVie, she focuses on generating intelligence to support strategic decision-making... Read More →
Speakers
avatar for Anshuman Panigrahi

Anshuman Panigrahi

Senior Director, Global Strategy and Analytics, Johnson & Johnson
Anshuman Panigrahi is Senior Director, Global Strategy & Analytics at Johnson & Johnson Innovative Medicine, where he leads portfolio analytics, forecasting, competitive intelligence and market research capabilities that inform enterprise planning and investment decisions. With more... Read More →
avatar for Hezekiah Blake

Hezekiah Blake

Senior Director, Competitive Intelligence, Amgen

Wednesday September 16, 2026 1:35pm - 2:05pm EDT
Junior Ballroom C

1:35pm EDT

Presentation
Wednesday September 16, 2026 1:35pm - 2:05pm EDT

 


Wednesday September 16, 2026 1:35pm - 2:05pm EDT
Junior Ballroom D

1:35pm EDT

What Pharma Needs From External Intelligence Partners in the AI Era
Wednesday September 16, 2026 1:35pm - 2:05pm EDT

Speakers
avatar for Ana Newnam

Ana Newnam

Competitive Intelligence Team Lead, BMS
Ana Newnam is the Competitive Intelligence Team Lead at Bristol Myers Squibb, part of the Enterprise Strategy group. Ana joined Bristol Myers Squibb in 2016 where she currently leads enterprise-wide strategic intelligence efforts spanning oncology, cell therapy, immunology, cardiovascular... Read More →
avatar for Michelle Sanchez

Michelle Sanchez

Senior Manager, Market Research & Competitive Intelligence, Ferring Pharmaceuticals
Wednesday September 16, 2026 1:35pm - 2:05pm EDT
Junior Ballroom F

2:10pm EDT

How to Deliver Intelligence that Motivates Action: The 5 Key Elements of a Compelling CI Narrative
Wednesday September 16, 2026 2:10pm - 2:40pm EDT
Our job as CI thought partners is to engage expert audiences, who are also human beings with limited attention and memory. Stories, relative to pure statistics & facts, are what stick best in their minds. Stories are more likely to impact beliefs and motivate action. Our minds are literally wired to respond to stories. 

But how can we leverage "storytelling" in communicating CI?

Even when the task is to describe trends, statistics & scientific facts, there are aspects we can leverage from great "storytelling" to better influence the way our audience feels about the CI we deliver. 

Attendees will hear about 5 key elements of compelling CI "storytelling". 

Speakers
avatar for Eileen Faucher, Ph.D.

Eileen Faucher, Ph.D.

Founder & Managing Director, Brass Tacks Insights
Eileen Faucher has been leading competitive intelligence for 16 years, including a decade as Founder and Managing Director at Brass Tacks Insights. In this role, she leads a team of PhD- and MD-level experts in developing long-term, competitive readiness thought partnerships. She... Read More →
Wednesday September 16, 2026 2:10pm - 2:40pm EDT
Junior Ballroom C

2:10pm EDT

Specialist Intelligence for Portfolio Strategy: Expert-Network-Backed Hypotheses, Tested Against Market Signals
Wednesday September 16, 2026 2:10pm - 2:40pm EDT
Every portfolio decision rests on a hypothesis about how the market will behave — and most go untested until the numbers land eighteen months later.
This session pairs the two halves of the answer. GOLF, GRG Health's KOL intelligence platform generates the hypothesis from independently moderated expert sessions with no sponsor in the room. With a verified 500K+ HCP network across 56+ countries, GOLF transforms expert oncology discussions into precise, actionable commercial insights — from signal to strategy, in real time.
AlfaKinetic, the real-time competitive intelligence platform from Anervea, a GRG Health company. 100+ sources monitored continuously, indication-first collection so day one is never empty, every signal scored against your own assets, and every decision tracked with a named owner.
Run a specialist-generated hypothesis against live signal and it resolves into one of four outcomes: confirmed, contradicted, early, or noise. Knowing which one you are in is the portfolio decision — demonstrated through a worked oncology case where belief and behaviour sat 67 points apart.
Bring the hypothesis your team is least certain about. We will show you which quadrant it falls in — and both of us will be on the floor for the duration.

Speakers
avatar for Rich Sommerkorn

Rich Sommerkorn

Associate Vice President - Business Development, GRG Health
Rich Sommerkorn leads direct-to-pharma partnerships at GRG Health, working with insights, commercial, brand and medical affairs teams on primary research and KOL intelligence programmes. Rich brings over 12 years in healthcare and insights, combining firsthand clinical experience... Read More →
avatar for Sanika Bhide, Ph.D.

Sanika Bhide, Ph.D.

Vice President - Enterprise Partnerships, Anervea
Sanika Bhide leads Anervea's agentic intelligence portfolio, working with competitive intelligence, commercial and medical affairs teams at Global Pharma accounts on AlfaKinetic deployments. She specialises in turning primary expert research into structured, testable market signal... Read More →
Wednesday September 16, 2026 2:10pm - 2:40pm EDT
Junior Ballroom D

2:10pm EDT

From fragmented data and outputs, to integrated, decision-ready insight
Wednesday September 16, 2026 2:10pm - 2:40pm EDT
Competitive Intelligence has long played an essential role in informing pharmaceutical decision making, yet its impact often remains uneven across functions and stages of the value chain. As data volumes grow and AI enabled technologies advance, organizations face a critical challenge: transforming intelligence from fragmented outputs into integrated, decision ready insight that drives meaningful action.  
  
This session explores how Competitive Intelligence can evolve from a traditional information provider into a trusted strategic thought partner, embedded across R&D, Commercial, Market Access, and Corporate Strategy. Drawing on Trinity’s integrated approach, we will examine how connecting disparate data sources, breaking functional silos, and applying technology with purpose can deliver actionable clarity, earlier decisions, and sustained competitive advantage. 
  
Attendees will gain practical perspectives on where CI is currently underutilized, how leading organizations are redefining CI’s role across functions, and what it takes to align people, process, and technology to unlock enterprisewide value. Join us to learn how an integrated CI ecosystem can move beyond dashboards and reports to spark smarter decisions, sooner - across the full pharmaceutical value chain. 

Speakers
avatar for Lindsey Acampa

Lindsey Acampa

Senior Director, Insights and Analytics, Dyne Therapeutics

avatar for Ben Doran

Ben Doran

Partner, Trinity Life Sciences

Wednesday September 16, 2026 2:10pm - 2:40pm EDT
Junior Ballroom F

2:40pm EDT

Networking Break
Wednesday September 16, 2026 2:40pm - 3:25pm EDT

Wednesday September 16, 2026 2:40pm - 3:25pm EDT
Grand Ballroom

3:25pm EDT

Faster Alerts Aren't Faster Decisions: Closing the Internal Half of Competitive Intelligence
Wednesday September 16, 2026 3:25pm - 3:55pm EDT
Avizum's agents monitor thousands of sources continuously and across languages, in production today across big pharma and small biotech and more than 30 indications. Alerts are validated and delivered within twenty minutes, filtered against intelligence questions rather than keyword strings, with the reasoning shown on every one. The first half of this session is 
that system running live. Seven years of work sits behind it, including the early wins nobody agreed on and the long flat stretch where the compounding was real but invisible — Avizum, introduced here for the first time, is where that work arrives. The second half addresses a problem better monitoring does not solve. In Day and Schoemaker's study of 380 organizations, whenever a company was late to a signal, someone inside had known all along; the leadership team had not. External monitoring is getting easier, which makes the internal half the bottleneck. Field insight thins at every level on the way up and reaches decision-makers late, or not at all, and the causes are organizational rather than technical. No one owns the internal layer, so no one builds it — and the country teams holding the best insight have the least incentive to share it. The session closes on what closing that gap requires, and what Avizum is building to do it.  


KEY TAKEAWAYS  
· See continuous, multi-language competitive monitoring running in production across 30+ indications  
· Understand why twenty-minute validated alerts change which questions CI can be asked to answer  
· Recognize the internal insight gap as an ownership problem rather than a technology problem  
· Assess where your own organization loses field signal on its way to the leadership team 

Speakers
avatar for Rita Lopes

Rita Lopes

VP, New Product Development, ATACANA Group
VP of New Product Development Rita Lopes holds a Ph.D. in Molecular Oncology and has a research background in Developmental Neuroscience. Over the past 15+ years, she has held Business and Market Intelligence roles across the pharmaceutical industry, with a focus on Oncology and Rare... Read More →
Wednesday September 16, 2026 3:25pm - 3:55pm EDT
Junior Ballroom C

3:25pm EDT

From Benchmark to Battleground: A Competitive Intelligence Lens on Pharma Productivity
Wednesday September 16, 2026 3:25pm - 3:55pm EDT
  • Reframing headline R&D metrics as competitor signals, from early-stage selectivity to development discipline 
  • What recent rank shifts among the top 25 tell us about which strategies are working 
  • Turning pipeline-to-patient benchmarks into an early-warning system for competitor strategy 

Speakers
avatar for Kelly Chamberlain, Ph.D.

Kelly Chamberlain, Ph.D.

Partner, Market Intelligence, Norstella / Evaluate
As a neuroscientist, consultant and commercial leader, Kelly brings more than 16 years of experience in the life sciences sector. She partners with insights, analytics, and commercial strategy teams to transform how pharmaceutical organizations capture and operationalize market intelligence... Read More →
Wednesday September 16, 2026 3:25pm - 3:55pm EDT
Junior Ballroom D

3:25pm EDT

From Four Hours to Fifteen Minutes: Rebuilding CI Monitoring With a Pharma CI Team
Wednesday September 16, 2026 3:25pm - 3:55pm EDT
  • Why a Competitive Intelligence lead described the monitoring service they were receiving as reading like it was written by ChatGPT. 
  • The engineering approach behind a 3-month rebuild of how CI teams at a pharma company monitor competitive landscapes. 
  • How time-to-report on earnings calls and congress readouts was cut from four hours to fifteen minutes.

Speakers
avatar for Duncan Emerton, Ph.D.

Duncan Emerton, Ph.D.

VP, Strategic Partnerships, Pharosyn
avatar for Stephen Cowley

Stephen Cowley

Co-Founder and CEO, Pharosyn
Stephen Cowley is co-founder and CEO of Pharosyn. With his co-founder Josh Hampson, he has taken his AI research at Cambridge and assembled a team of former CI and strategy consultants and AI engineers to ship AI for pharma competitive intelligence teams.
Wednesday September 16, 2026 3:25pm - 3:55pm EDT
Junior Ballroom F

4:00pm EDT

AI-Assisted Oncology CI Toolkit: SOC Benchmarking, Abstract Prioritization, and Outcome Prediction
Wednesday September 16, 2026 4:00pm - 4:30pm EDT
Applying AI to structured oncology data enables complementary CI workflows spanning current landscape assessment, evidence prioritization, and outcome prediction. 
 
  • SOC benchmarking: Visualize competitive and market dynamics through AI-powered maps integrating current and emerging SOC, key regimens, efficacy, safety, network meta-analysis results, market-share estimates, and future scenario modeling. 
  • Abstract prioritization: Multi-LLM ranking of abstracts using impact scores and supporting rationales aligned with customer-defined priorities. 
  • Outcome prediction: Forecast upcoming or immature trial outcomes using machine learning and LLM models trained on structured oncology data. 

Speakers
avatar for Bruno Larvol

Bruno Larvol

CEO, LARVOL
Bruno Larvol is the CEO of LARVOL, an AI-first oncology intelligence company serving leading pharmaceutical and healthcare organizations worldwide. With a background in strategy consulting and deep expertise in the pharma and biotech industries, Bruno leads a globally distributed... Read More →
Wednesday September 16, 2026 4:00pm - 4:30pm EDT
Junior Ballroom C

4:00pm EDT

From Data Overload to Decision Confidence: AI-Driven Competitive Intelligence in Pharma
Wednesday September 16, 2026 4:00pm - 4:30pm EDT
Life sciences CI teams are navigating an explosion of data, from clinical trials and regulatory updates to patents, publications, and market activity. The challenge is no longer finding information; it is turning fragmented signals into timely, decision-ready intelligence the whole business can trust. 
 
This session explores how AI-driven competitive intelligence is changing that. As general AI puts fast answers in everyone's hands, the differentiator for CI is no longer speed alone but trust: intelligence you can act on because you can prove where it came from. We will look at how conversational, AI-driven approaches let teams ask questions in plain language and get sourced, decision-ready answers, and how that democratizes intelligence across R&D, commercial, and executive stakeholders without sacrificing rigor or governance. 
Attendees will leave with a practical model for evolving their function from reactive reporting to proactive strategic partnership, and a framework for evaluating AI-driven CI in an era where the source of an answer matters as much as the answer itself. 
 
Key takeaways 
 
  • How to turn fragmented signals into decision-ready intelligence teams can act on and defend 
  • Why trust, source traceability, and governance are becoming the real differentiators for AI-driven CI 
  • How conversational, self-serve intelligence democratizes CI across the organization 
  • A maturity model for moving from reactive reporting to proactive strategic partnership 
 

Speakers
avatar for Sheri Larsen

Sheri Larsen

Chief Product Officer, Northern Light
Sheri Larsen converts market opportunity into product momentum, orchestrating engineering, content, and security teams so every release accelerates decision-making. A Northern Light original, she built the firm’s product-management discipline to ensure innovation lands with measurable... Read More →
Wednesday September 16, 2026 4:00pm - 4:30pm EDT
Junior Ballroom D

4:00pm EDT

From Signals to Stakeholder Impact: ADN CI Platform as the Next-Generation CI Operating Model for Pharma
Wednesday September 16, 2026 4:00pm - 4:30pm EDT
 
  • Pharma CI needs an operating model, not just more data - CI teams already have access to multiple databases, news feeds, internal documents, and vendor reports. The real challenge is converting fast-moving competitive signals into validated, decision-ready intelligence that reaches the right stakeholders before business decisions are made. 
 
  • ADN CI Platform connects the full CI workflow from signal to stakeholder impact: We will show how ADN CI Platform supports the complete CI operating lifecycle: signal detection, triage, KIT/KIQ-driven monitoring, analyst drafting, CI Lead review, client approval, stakeholder dissemination, and repository reuse. 
  • AI-enabled efficiency with human-validated intelligence governance: We will discuss how LLMs can accelerate monitoring, summarization, synthesis, and draft generation, while human expertise remains central for validation, strategic interpretation, approval, and controlled dissemination in a pharma CI environment. 

Speakers
avatar for Virendra Kumar

Virendra Kumar

Chief Executive Officer, AdametNext
Viren is the founder of Adamet-Next, a future readiness partner for biopharma companies. He brings deep experience in pharma competitive intelligence, business insights, and strategic intelligence delivery across therapeutic areas. In the past, he has led CI verticals at companies... Read More →
avatar for Ziya Pailwan

Ziya Pailwan

Associate Director, AdametNext
Ziya is a seasoned competitive intelligence professional with extensive experience in delivering competitive and strategic intelligence across biopharma markets. Ziya focuses on translating complex clinical, regulatory, scientific, and competitor developments into structured, decision-ready insights that support strategic decision-makin... Read More →
Wednesday September 16, 2026 4:00pm - 4:30pm EDT
Junior Ballroom F

4:30pm EDT

Panel: How will AI Impact the Speed and Success Rate of Drug Development?
Wednesday September 16, 2026 4:30pm - 5:15pm EDT
Pointers to put Competitive Intelligence Teams ahead of the curve
 
  • AI promises to accelerate drug discovery, with better compounds entering the clinic that both reduce the time and money required to develop a drug. Is this already happening? The panel will discuss the challenges of applying AI and machine learning to compound discovery, preclinical testing, identifying the right patients, biomarker development, trial management, and ultimately in silico trials.
  • Discuss what CI Teams should look for to tell hype from reality as companies claim AI based success. Discuss which emerging trends, companies, technologies, and development milestones to pay attention to.  
  • Examine how AI-driven advances could reshape competitive strategy over the next decade.

Moderators
avatar for Ben Weintraub

Ben Weintraub

President, inThought Research

Speakers
avatar for Eddine Maiza

Eddine Maiza

Global Head, Competitive Intelligence, Gilead
avatar for Christopher Roselle, Ph.D.

Christopher Roselle, Ph.D.

Director, Strategy & Operations, Recursion
Christopher Roselle is the Director of Strategy & Operations at Recursion, where he works
across the company’s platform and pipeline on portfolio and operational strategy.
Prior to joining Recursion, Chris worked at Boston Consulting Group, advising
biopharmaceutical companies on... Read More →
Wednesday September 16, 2026 4:30pm - 5:15pm EDT
Junior Ballroom C

4:30pm EDT

Panel: Beyond the Brand: How Enterprise Competitive Intelligence Shapes Strategic Decisions
Wednesday September 16, 2026 4:30pm - 5:15pm EDT
What should Enterprise CI actually be responsible for? 
 


  • Define how enterprise competitive intelligence differs from brand-, asset-, and therapeutic area-focused intelligence—and where each creates the greatest value 

  • Examine how macro trends, disruptive technologies, policy changes, and competitive shifts are reshaping long-term portfolio and enterprise strategy 

  • Explore how enterprise intelligence partners with commercial, R&D, portfolio strategy, business development, and executive leadership to connect insights across the organization 

  • Identify which strategic questions are best answered by enterprise intelligence versus brand- and asset-level teams 
Moderators
avatar for Veronica Granatiero, PharmD, Ph.D.

Veronica Granatiero, PharmD, Ph.D.

Associate Director, Oncology Competitive Intelligence, BMS

Speakers
avatar for Olesya Levsh	​​​​

Olesya Levsh ​​​​

Senior Director, Competitive Intelligence, Cullinan Therapeutics, Inc.

avatar for Hezekiah Blake

Hezekiah Blake

Senior Director, Competitive Intelligence, Amgen

avatar for Jordan Lord

Jordan Lord

Enterprise Competitive Intelligence Lead, AbbVie
Wednesday September 16, 2026 4:30pm - 5:15pm EDT
Junior Ballroom D

4:30pm EDT

Panel: Design AI Workflows Intelligence Teams Actually Trust
Wednesday September 16, 2026 4:30pm - 5:15pm EDT
  • Identify where AI can—and cannot—add value across the R&D CI workflow, from monitoring emerging science, competitors, new targets and technologies to synthesizing signals and supporting strategic initiatives and partnering decisions.
  • Examine what it takes to trust AI-generated intelligence in high-stakes R&D decisions, including source validation, transparency, data quality, hallucination risk and the role of human scientific expertise in interpreting and challenging AI outputs.
  • Explore how R&D CI teams can combine AI with human judgment to move from information gathering to strategic foresight, connecting fragmented scientific and competitive signals to identify emerging opportunities, anticipate threats and help R&D leaders make better decisions.
Moderators
avatar for Rajesh Shinde

Rajesh Shinde

Partner, Life Sciences Analytics & AI, Capgemini-IBO Next

Speakers
avatar for Timothy Flood

Timothy Flood

Director Global Competitive Intelligence, Genmab

avatar for Iffat Ali, Ph.D.

Iffat Ali, Ph.D.

Senior Director, Competitive Intelligence, Gilead

avatar for Harry Yuan, Ph.D.

Harry Yuan, Ph.D.

Associate Director, Scientific & Competitive Analysis, Takeda Oncology
Harry Yuna, PhD, MBA, is the Global CI Lead of the Hematologic Oncology franchise at Takeda Oncology. His expertise covers broad disease areas including myeloproliferative neoplasms, lymphomas, leukemia, and multiple myeloma etc. As the CI Lead, he is responsible for intelligence... Read More →
Wednesday September 16, 2026 4:30pm - 5:15pm EDT
Junior Ballroom F

5:15pm EDT

Roundtables
Wednesday September 16, 2026 5:15pm - 6:00pm EDT
  1. The Future CI Leader: Skills, Capabilities & Career Path- Eddine Maiza, Global Head, Competitive Intelligence, Gilead - (Essex)
  2. From Pilot to Practice: Deploying AI Inside the CI Function- Suzanne Caruso,  President, Strategic Intelligence and Clinical & Regulatory, Norstella (Skylands)
  3. The Macro Trends Shaping Competitive Intelligence - Christpher Salatto, Senior Director, Pfizer (Gateway)
  4. Who is a CI expert in the age of AI? Balaji Bharatwaj, CI Director, Pfizer (Columbia)
  5. Building a Competitive Intelligence Function Leadership Can't Ignore - Noam Fishman, Associate Director, Market Research & Competitive Intelligence, Ferring Pharma (Holland) 
  6. How Competitive Intelligence Evolves As Organizations Grow - Timothy Flood, Director Global Competitive Intelligence,  Genmab (Lincoln)
  7. Everyone Uses Competitive Intelligence. So Why Do So Few People Understand It? Nilesh Sahi, Global Head Competitive & Strategic Intelligence, Ipsen (Liberty)
Speakers
avatar for Nilesh Sahi

Nilesh Sahi

Global Head, Competitive & Strategic Intelligence, Ipsen

avatar for Suzanne Caruso

Suzanne Caruso

President, Citeline Clinical, Regulatory, and Strategic Intelligence, Norstella
Suzanne Caruso is a senior business executive and clinical trial study start-up expert with over 15 years of experience in the pharmaceutical industry. As President, Strategic Intelligence and Clinical & Regulatory at Norstella, Suzanne leverages her expertise in data analytics and... Read More →
avatar for Noam Fishman

Noam Fishman

Associate Director, Market Research and Competitive Intelligence, Ferring Pharmaceuticals
Noam Fishman serves as Associate Director, Market Research and Competitive Intelligence at Ferring Pharmaceuticals, where he supports business stakeholders through market research, competitive intelligence, forecasting, and analytics. He is part of the Insights and Analytics team... Read More →
avatar for Eddine Maiza

Eddine Maiza

Global Head, Competitive Intelligence, Gilead
avatar for Balaji Bharatwaj

Balaji Bharatwaj

Director of Competitive Intelligence, Pfizer
Balaji Bharatwaj is a Director of Competitive Intelligence at Pfizer, leading Competitive Intelligence activities for the Immunology & Inflammation portfolio. He has also supported Corporate Competitive Intelligence, Internal Medicine, and Anti-Infectives, providing insights to inform... Read More →
avatar for Timothy Flood

Timothy Flood

Director Global Competitive Intelligence, Genmab

Wednesday September 16, 2026 5:15pm - 6:00pm EDT

6:00pm EDT

Cocktail Reception
Wednesday September 16, 2026 6:00pm - 7:00pm EDT

Wednesday September 16, 2026 6:00pm - 7:00pm EDT
Grand Ballroom
 
Share Modal

Share this link via

Or copy link

Filter sessions
Apply filters to sessions.
Filtered by Date -